Suvratoxumab (INN; development code MEDI4893) is a human monoclonal antibody designed for the prevention of nosocomial pneumonia caused by Staphylococcus aureus.

This drug was developed by MedImmuneStatement On A Nonproprietary Name Adopted By The USAN Council - Suvratoxumab, American Medical Association.

References